Patients who have received wide field radiotherapy ?  days (defined as > % of volume of pelvic bones or equivalent) or limited field radiation for palliation <  days prior to randomization
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to treatment start, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Radiotherapy with a wide field of radiation within  weeks,
Received radiotherapy =<  days or limited field radiation for palliation =<  days prior to registration, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= -% of the bone marrow was irradiated
Patient has received wide field radiotherapy (including therapeutic radioisotopes such as strontium ) =<  days or limited field radiation for palliation =<  days prior to starting trial medications or has not recovered from side effects of such therapy
Participant has received radiotherapy ? weeks or limited field radiation for palliation ? weeks prior to starting study drug, and who has not recovered to Grade  or better from related side effects of such therapy (with the exception of alopecia) and/or for whom ?% of the bone marrow was irradiated.
Chemotherapy or limited field radiotherapy within  weeks, wide field radiotherapy within  weeks, or nitrosoureas or mitomycin C within  weeks prior to entering the study
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) or in whom >= % of the bone marrow was irradiated
Radiotherapy with a limited field of radiation for palliation within  week of the first dose of study treatment, with the exception of patients receiving radiation to more than % of the bone marrow or with a wide field of radiation which must be completed within  weeks of the first dose of study treatment.
Radiotherapy with a wide field of radiation within  weeks or radiotherapy with a limited field of radiation for palliation within  weeks of the first dose of study treatment.
Wide field radiotherapy (including therapeutic radioisotopes such as strontium ) administered ? days or limited field radiation for palliation ? days prior to starting study drug or has not recovered from side effects of such therapy.
Has received wide field radiotherapy (including therapeutic radioisotopes such as radium ) ?  days or limited field radiation for palliation ?  days prior to starting study drug or has not recovered from side effects of such therapy.
Radiotherapy treatment to more than % of the bone marrow or with a wide field of radiation within  weeks, or palliative radiation therapy within  weeks of the first dose of study drug treatment.
Received chemotherapy, radiotherapy (to more than % of the bone marrow or with a wide field of radiation), or biologic therapy within the last  days
Prior chest radiotherapy ?  months, wide field radiotherapy ?  days (defined as > % of volume of pelvic bones or equivalent), or limited field radiation for palliation ?  days prior to study treatment - Such patients must have recovered adequately from any side effects of such therapy.
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
The last radiation therapy within  weeks prior to starting study treatment, or limited field of radiation for palliation within  weeks of the first dose of study treatment
Wide field radiotherapy within  days of cycle /day  or active side effects of such therapy
Radiotherapy for extended field within prior  weeks or limited field within prior  weeks;
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Patients who have received wide field radiotherapy ?  days (defined as > % of volume of pelvis bones or equivalent) or limited field radiation for palliation <  days prior to study registration or those patients who have not recovered adequately from side effects of such therapy
Patients who have received wide field radiotherapy =<  days (defined as > % of volume of pelvic bones or equivalent) or limited field radiation for palliation <  days prior to study registration or those patients who have not recovered adequately from side effects of such therapy
Received wide field radiotherapy =<  days or limited field radiation for palliation =<  days prior to registration or who have not recovered from side effects of such therapy
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
Received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to registration, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >=  percent (%) of the bone marrow was irradiated
Patient has received radiotherapy ?  weeks or limited field radiation for palliation ?  weeks prior to enrollment, and who has not recovered to grade  or better from related side effects of such therapy
Extended field radiation within prior  weeks or limited field radiation within prior  weeks
Patient who has received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered to grade  or better from related side effects of such therapy (except alopecia)
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Patient who has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Prior full field radiotherapy <  weeks or limited field radiotherapy <  weeks prior to first study drug administration
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
Subject has received radiotherapy ?  weeks or limited field radiation for palliation ?  weeks prior to starting IP, and/or from whom ? % of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within  days of study entry.
Patients who have received wide field radiotherapy ?  days (defined as > % of volume of pelvic bones or equivalent) or limited field radiation for palliation <  days prior to cycle  day  or those patients who have not recovered adequately from side effects of such therapy
Patient has received radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom >= % of the bone marrow was irradiated
Radiotherapy with a wide field of radiation within  weeks or radiotherapy with a limited field of radiation for palliation within  week of the first dose of study treatment with the exception of patients receiving radiation to more than % of the bone marrow which must be completed within  weeks of the first dose of study treatment.
Participant has had radiotherapy ?  weeks or limited field radiation for palliation
Patient who has received radiotherapy within less than or equal to  weeks or limited field radiation for palliation within less than or equal to  weeks prior to starting study drug, and who has not recovered to grade  or better from related side effects of such therapy (exceptions include alopecia) and/or in whom greater than or equal to % of the bone marrow was irradiated
Patient who has received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered to grade  or better from related side effects of such therapy (except alopecia)
Radiotherapy treatment to more than % of the bone marrow or with a wide field of radiation within  weeks of the first dose of study drug.
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
Wide field radiotherapy (including therapeutic radioisotopes such as strontium-) administered ? days or limited field radiation for palliation ? days prior to starting study drug or has not recovered from side effects of such therapy
Patients who have received wide field radiotherapy ?  weeks or limited field radiation for palliation <  weeks prior to screening or who have not recovered adequately from side effects of such therapy.
Last radiation therapy within  weeks prior starting study treatment, or limited field of radiation for palliation within  days of the first dose of study treatment
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
The last radiation therapy within  weeks prior to starting study treatment, or limited field of radiation for palliation within  days of the first dose of study treatment.
Received wide field radiotherapy =<  weeks, or SRS or gamma knife for brain metastasis =<  weeks or limited field radiation for palliation =<  weeks prior to starting either BYL or BKM or have not recovered from side effects of such therapy
Treatment with full field radiation therapy within  weeks or limited field radiation therapy within  weeks prior to the first dose of study medication
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have received wide field radiotherapy =<  weeks or limited field radiation for palliation =<  weeks prior to starting study drug or who have not recovered from side effects of such therapy
Subject has received radiotherapy ?  weeks or limited field radiation for palliation ?  weeks prior to starting investigational product (IP), and/or from whom ? % of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
Radiotherapy < or =  weeks or limited field radiation for palliation < or =  weeks prior to starting with the investigational product.
Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within  weeks before the first dose of study drug
Radiotherapy treatment to more than % of the bone marrow or with a wide field of radiation within  weeks of the first dose of study drug treatment, or palliative radiation therapy within  weeks of the first dose of study drug treatment
Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within  weeks before the first dose of study drug
Patients who have received wide field radiotherapy ?  days (defined as > % of volume of pelvic bones or equivalent) or limited field radiation for palliation <  days prior to starting study treatment or those patients who have not recovered adequately from side effects of such therapy
